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Summary 
Heightened systemic inflammation contributes to cardiovascular (CVD) events in people 
living with HIV (PLWH), though not all PLWH develop CVD, thus suggesting a genetic 
modifying role. We examined GCH1 polymorphisms, which have been associated with 
reduced endothelial function in European populations with CVD and increased inflammation, 
in a racially diverse cohort of U.S. PLWH initiating antiretroviral therapy (ART). GCH1 
polymorphisms differed by race and were not associated flow-mediated dilation or carotid 
intima media thickness before or after 48 weeks of ART. 
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Introduction 
PLWH have an increased risk of CVD[1]. Elevated markers of generalized inflammation 
[interleukin-6 (IL-6), high sensitivity C-reactive protein (hsCRP)] predict HIV-CVD events 
[2]. However, not all patients with HIV develop CVD despite increased systemic 
inflammation, which suggests the possibility of unknown modulators between the two. 
Recent data from general population studies have shown that tetrahydrobiopterin (BH4) 
influences atherosclerosis [3]. Endothelial nitric oxide synthase (eNOS) requires BH4 as an 
enzymatic cofactor. Without BH4, superoxide radicals are generated instead of nitric oxide. 
Vascular bioavailability of BH4 is dependent on GTP-cyclohydrolase (GTPCH), which is the 
key rate-limiting enzyme in the generation of BH4. GCH1 is the gene encoding GTPCH and 
is upregulated in endothelial cells when stimulated by IL-6, hsCRP, and lipopolysaccharide. 
Thus, vascular inflammation induces expression of GCH1, which in turn prompts greater 
production of BH4 to maximize eNOS function and maintain endothelial function. A specific 
GCH1 haplotype [rs8007267G>A, rs3783641A>T, rs10483639C>G, or ‘ATG’] is associated 
with reductions in GTPCH, nitric oxide, and endothelial function in the setting of acute 
inflammation, but only to date in very specific, ethnically homogenous European populations 
with known CVD [3]. Heterozygotes for this haplotype are thought to have modestly lower 
BH4 levels whereas homozygotes have even lower BH4 availability [3-5]. Therefore, we 
performed the current study to determine how the GCH1 haplotype relates to CVD risk in a 
diverse population of patients with chronically elevated systemic inflammation, as is found in 
U.S. PLWH.   
 
Methods 
To address our study objective, we combined data from two AIDS Clinical Trials Group 
studies (A5260s and A5152s) in which genome-wide association studies were performed and 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
for which the participants had undergone measurements of flow-mediated dilation (FMD) of 
the brachial artery, a measure of endothelial function, and carotid intima media thickness 
(CIMT), a measure of cumulative arterial injury. We determined the frequencies for the 
GCH1 ATG haplotype and also determined the frequencies for the rs841C>T polymorphism, 
which has also been associated with reduced GCH1 expression and endothelial function in 
other populations [4, 5]. Data were analyzed at study entry and at follow-up times of 24 and 
48 weeks (CIMT was done only measured at week 48).   
Haplotypes were determined using the haplo.stat package in R, which utilizes the 
Expectation-Maximization (EM) algorithm to determine haplotypes when linkage phase is 
ambiguous. Fisher’s exact test was performed to test for Hardy-Weinberg equilibrium. 
Analysis of Covariance models were constructed to determine if there were significant 
differences in FMD and CIMT results by haplotype/SNP group with adjustments for HIV-1 
RNA level and ACTG trial group. Comparisons were also performed to identify significant 
associations between FMD and CIMT with IL-6 and hsCRP.  Outcomes were analyzed both 
as cross-sectional results at each baseline and at each follow-up time point and as change 
from baseline to follow-up. Adjustments for multiple testing were not performed. 
 
Results 
For the 296 participants with the genetic and imaging data available from these combined 
trials, the mean (SD) age was 36.8 (10.3) years, with 9.1% female, 30.5% black, 13.2% 
Hispanic, and 53.6% white (Table 1). At trial entry (week 0), the mean (SD) CD4 was 344 
(187) cells/μL, HIV-1 log10 RNA level was 4.56 (0.70) copies/mL, FMD% was 4.71 (2.65), 
and CIMT was 0.66 (0.11) mm. The upper tertile cutoffs for IL-6 and hsCRP were 2.2 pg/mL 
and 2.1 mg/L, respectively. Most of the study population did not carry the GCH1 ATG 
haplotype; only 18 (6.1%) were hemizygous and 2 (<1%) were homozygous. For rs841C>T, 
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182 (61.5%) were wildtype, 95 (32.1%) were hemizygous, and 19 (6.4%) were homozygous. 
All SNPs of interest met Hardy-Weinberg equilibrium except for rs8007267.   
There were no significant associations between either the GCH1 ATG haplotype or 
rs841C>T polymorphism with either FMD or CIMT at any time point or for changes in FMD 
or CIMT within the entire cohort (Table 1) or in any racial subgroup (data not shown). We 
also did not find significant associations between the ATG haplotype of rs841 
polymorphisms and either IL-6 or hsCRP in the entire study group or in any racial subgroup 
(data not shown). 
 
Discussion 
Contrary to expectations, we found no associations between FMD and CIMT with a GCH1 
haplotype previously found in a European population to be associated with reduced 
endothelial function in the setting of acute inflammation and with cardiovascular disease. In 
this European study of 376 white individuals [3], the GCH1 ATG was found in 30% of the 
study population (27% as hemizygous and 3% as homozygous). Moreover, BH4 levels and 
FMD were significantly reduced in those carrying this GCH1 haplotype, but only in those 
with higher hsCRP levels. Assuming that untreated HIV infection may be a CVD equivalent 
condition, we hypothesized that FMD would be more impaired and CIMT greater in those 
with higher levels of systemic inflammation, measured as hsCRP or IL-6. The lack of 
significant associations in our study may be due to the very low frequency of this GCH1 
haplotype (and thus lower power to detect associations) in our diverse U.S. study cohort. 
Interestingly, 20 of the 21 individuals with this haplotype were black (20/90) with none in the 
white subgroup (0/158). In fact, based on the gene frequencies actually detected in our study 
sample, we would need to triple our study sample in order to have power greater than 0.80 to 
detect differences in FMD and CIMT at the various time points assessed. The FMD values in 
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our study and in the European study were similar, thus there likely were no systematic 
differences in endothelial function measurements to explain the lack of association with 
GCH1 in the current study. It is also possible that the relationship between the GCH1 
haplotype and endothelial function may be restricted to Europeans and/or those with 
established CVD, which was not the case in our HIV+ study population. Alternatively, there 
may be differences in linkage disequilibrium with other genes truly responsible for 
endothelial function integrity which may exist between European and U.S. populations 
leading to the discrepant results observed. Of note, studies in other populations have also 
found negative or opposite associations (and also with different allele frequencies) between 
this GCH1 haplotype and BH4 levels, endothelial function, and/or other CVD parameters [6-
10]. We also examined a polymorphism in rs841 that had also previously been associated 
with reduced GHC1 expression but again did not find associations with CVD risk as 
measured by FMD and CIMT. Thus, our data do not support a relationship between the 
GCH1 polymorphisms tested and FMD or CIMT in U.S. HIV+ individuals without 
established CVD either before or after ART initiation. We acknowledge that without direct 
measurement of circulating BH4 levels, we could not confirm the underlying gene-function 
relationship in this study sample.  
These results reinforce the requirement to confirm genetic associations across 
different geographical, racial, and ethnic populations. Future studies should examine other 
potential genetic predispositions to greater CVD risk in this population.  
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Table 1. Associations between GCH1 polymorphisms, IL-6, and hsCRP with FMD and 
CIMT. 
   ATG haplotype rs841 Entry IL-6 Entry hsCRP 
Charact
eristic 
W
ee
k 
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e 
(n=2
76) 
Hemiz
ygous 
(n=18) 
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(n=2) 
P-
val
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(n=1
79) 
TC 
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TT 
(n=
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ue 
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er 
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es 
(n=1
68) 
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per 
terti
le 
(n=
85) 
P-
val
ue 
Low
er 
tertil
es 
(n=1
93) 
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per 
terti
le 
(n=
97) 
P-
val
ue 
Female 
sex,  
n (%) 
  26 
(9.4
) 
1 (5.6) 0 (0) 1.0
0 
15 
(8.2
) 
11 
(11.
1) 
1 
(5.6
) 
.70 13 
(7.7
) 
9 
(10.
6) 
.48 14 
(7.3
) 
11 
(11.
3) 
.27 
White, 
n (%) 
  158 
(57.
5) 
0 (0) 0 (0) <.
01 
97 
(54.
2) 
51 
(52.
0) 
10 
(55.
6) 
.07 89 
(53.
3) 
39 
(45.
9) 
.62 109 
(56.
5) 
46 
(47.
9) 
.44 
Black, 
n (%) 
  71 
(25.
8) 
17 
(94.4) 
2 (100)  62 
(34.
6) 
24 
(24.
5) 
4 
(22.
2) 
 50 
(29.
9) 
32 
(37.
7) 
 56 
(29.
0) 
32 
(33.
3) 
 
Hispani
c,  
n (%) 
  38 
(13.
8) 
1 (5.6) 0 (0)  15 
(8.4
) 
20 
(20.
4) 
4 
(22.
2) 
 23 
(13.
8) 
11 
(12.
9) 
 24 
(12.
4) 
14 
(14.
6) 
 
Other, n 
(%) 
  8 
(2.9
) 
0 (0) 0 (0)  5 
(2.8
) 
3 
(3.1
) 
0 
(0) 
 5 
(3.0
) 
3 
(3.5
) 
 4 
(2.1
) 
4 
(4.2
) 
 
FMD, 
% 
0 2
6
8 
4.74 
(2.6
8) 
4.34 
(2.86) 
5.85 (.) .78 4.71 
(2.9
4) 
4.6
5 
(2.2
5) 
5.1
6 
(2.2
7) 
.77 4.75 
(2.4
5) 
5.2
2 
(3.0
9) 
.21 4.52 
(2.4
3) 
5.1
3 
(3.1
0) 
.08 
 24 2
4
3 
5.05 
(2.7
6) 
4.19 
(2.55) 
n/a .24 5.06 
(2.8
8) 
5.9
7 
(2.6
3) 
4.6
5 
(2.2
2) 
.83 4.77 
(2.4
8) 
5.4
1 
(3.1
3) 
.11 4.84 
(2.3
9) 
5.3
6 
(3.3
9) 
.17 
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 48 2
1
7 
4.98 
(2.6
6) 
3.90 
(1.86) 
4.06 (.) .31 4.96 
(2.6
0) 
4.7
7 
(2.6
3) 
5.0
5 
(2.9
0) 
.87 5.04 
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2) 
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8 
(2.6
3) 
.35 5.00 
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7) 
4.7
7 
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5) 
.56 
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24  
2
3
8 
0.28 
(2.8
0) 
-0.17 
(2.96) 
n/a .55 0.30 
(3.1
0) 
0.2
7 
(2.4
4) 
-
0.2
9 
(1.1
7) 
.73 -
0.05 
(2.4
7) 
0.1
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(3.0
3) 
.67 0.31 
(2.6
2) 
0.1
4 
(3.2
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2
1
2 
0.03 
(2.9
7) 
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(2.32) 
-1.79 
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0.04 
(3.2
1) 
-
0.0
8 
(2.6
3) 
0.0
6 
(1.7
5) 
.99 0.25 
(2.8
4) 
-
0.5
8 
(3.0
8) 
.06 0.29 
(2.8
4) 
-
0.6
3 
(3.0
4) 
.03
* 
CIMT, 
mm 
0 2
4
4 
0.66 
(0.1
1) 
0.70 
(0.07) 
0.53 (.) .26 0.66 
(0.1
0) 
0.6
8 
(0.1
4) 
0.6
6 
(0.0
9) 
.29 0.66 
(0.1
1) 
0.6
8 
(0.1
1) 
.08 0.66 
(0.1
1) 
0.6
7 
(0.1
0) 
.88 
 48 2
2
7 
0.68 
(0.1
2) 
0.70 
(0.07) 
0.55 (.) .45 0.67 
(0.1
0) 
0.7
0 
(0.1
4) 
0.6
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(0.0
9) 
.26 0.67 
(0.1
1) 
0.6
9 
(0.1
1) 
.11 0.68 
(0.1
1) 
0.6
8 
(0.1
1) 
.76 
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k 0 
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2
2
7 
0.01 
(0.0
2) 
0.01 
(0.02) 
0.02 (.) .67 0.01 
(0.0
2) 
0.0
1 
(0.0
2) 
0.0
1 
(0.0
2) 
.31 0.01 
(0.0
2) 
0.0
1 
(0.0
2) 
.23 0.01 
(0.0
2) 
0.0
1 
(0.0
2) 
.17 
The ATG haplotype consists of rs8007267G>A, rs3783641A>T, rs10483639C>G. IL-6, 
interleukin-6; hsCRP, high sensitivity C-reactive protein; FMD, flow-mediated dilation; 
CIMT, carotid intima media thickness. 
Values are frequencies (percentages) for categorical variables and means (standard 
deviations).  P-values are from Fisher’s Exact tests and ANOVAs, respectively.  
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Demographic variables are from baseline only.  A “(.)” indicates there was only one 
observation and so no standard deviation could be calculated.  Analyses were also adjusted 
for viral load and for trial (GWAS) group, with similar (non-attenuated) results.  Analysis 
data sets include those with values at follow-up time periods (weeks 24 and 48) and so may 
be smaller than the full sample sizes at baseline.  
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